Journal of Molecular Medicine

, Volume 82, Issue 3, pp 182–188

Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients

  • Aimée D. C. Paulussen
  • Ronaldus A. H. J. Gilissen
  • Martin Armstrong
  • Pieter A. Doevendans
  • Peter Verhasselt
  • Hubert J. M. Smeets
  • Eric Schulze-Bahr
  • Wilhelm Haverkamp
  • Günter Breithardt
  • Nadine Cohen
  • Jeroen Aerssens
Original Article

DOI: 10.1007/s00109-003-0522-z

Cite this article as:
Paulussen, A.D.C., Gilissen, R.A.H.J., Armstrong, M. et al. J Mol Med (2004) 82: 182. doi:10.1007/s00109-003-0522-z

Abstract

Administration of specific drugs may occasionally induce acquired long QT syndrome (aLQTS), a disorder that predisposes to ventricular arrhythmias, typically of the torsade de pointes (TdP) type, and sudden cardiac death. “Forme fruste” mutations in congenital LQTS (cLQTS) genes have been reported repeatedly as the underlying cause of aLQTS, and are therefore considered as an important risk factor. We evaluated the impact of genetic susceptibility for aLQTS through mutations in cLQTS genes. Five cLQTS genes (KCNH2, KCNQ1, SCN5A, KCNE1, KCNE2) were thoroughly screened for genetic variations in 32 drug-induced aLQTS patients with confirmed TdP and 32 healthy individuals. Missense forme frust mutations were identified in four aLQTS patients: D85N in KCNE1 (two cases), T8A in KCNE2, and P347S in KCNH2. Three other missense variations were found both in patients and controls, and are thus unlikely to significantly influence aLQTS susceptibility. In addition, 13 silent and six intronic variations were detected, four of which were found in a single aLQTS patient but not in the controls. We conclude that missense mutations in the examined cLQTS genes explain only a minority of aLQTS cases.

Keywords

Long QT syndromeDrug-inducedArrhythmiaMutation analysis

Abbreviations

cLQTS

Congenital long QT syndrome

aLQTS

Acquired long QT syndrome

TdP

Torsade de pointes

ECG

Electrocardiogram

QTc

Corrected QT

PCR

Polymerase chain reaction

LD

Linkage disequilibrium

Copyright information

© Springer-Verlag 2004

Authors and Affiliations

  • Aimée D. C. Paulussen
    • 1
  • Ronaldus A. H. J. Gilissen
    • 1
  • Martin Armstrong
    • 1
  • Pieter A. Doevendans
    • 3
  • Peter Verhasselt
    • 2
  • Hubert J. M. Smeets
    • 4
  • Eric Schulze-Bahr
    • 5
  • Wilhelm Haverkamp
    • 5
  • Günter Breithardt
    • 5
  • Nadine Cohen
    • 1
  • Jeroen Aerssens
    • 1
  1. 1.Department of PharmacogenomicsJohnson & Johnson Pharmaceutical Research and DevelopmentBeerseBelgium
  2. 2.Department of Functional GenomicsJohnson & Johnson Pharmaceutical Research and DevelopmentBeerseBelgium
  3. 3.Department of CardiologyAcademic HospitalMaastrichtThe Netherlands
  4. 4.Department of Genetics and Cell BiologyCardiovascular Research Institute Maastricht (CARIM)MaastrichtThe Netherlands
  5. 5.Department of Cardiology and Angiology, Hospital of the Westfalian Wilhelms-University, Institute for Arteriosclerosis Research University of MünsterMünsterGermany